Clinical trials: Gastroparesis With Diabetes Mellitus
Diabetic Gastroparesis, Idiopathic Gastroparesis
Effect of TAK-954 on Gastrointestinal and Colonic Transit in Diabetic or Idiopathic Gastroparesis Participants
The purpose of this study is to evaluate the dose-dependent effects of TAK-954 on gastric emptying time of solids in participants with diabetic or idiopathic gastroparesis assessed by scintigraphy.
- Trial name
- NCT03281577
- Testing
- TAK-954
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Takeda
Diabetic Gastroparesis
Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis
The purpose of this study is provide confirmation of the safety and efficacy of Metoclopramide Nasal Spray compared to placebo in reducing the symptoms of diabetic gastroparesis in adult women.
- Trial name
- NCT02025725
- Testing
- Metoclopramide Nasal Spray
- Where
- 50 sites in United States
- Volunteers
- 205 people
- Sponsor
- Evoke Pharma
Diabetic Gastroparesis
Diabetic Gastroparesis Efficacy/Safety Study of TZP-102
The purpose of this study is to test the safety and effectiveness of 10 mg TZP-102 given prior to meals three times a day compared to placebo (capsule that looks like active study drug but contains no active drug), administered…
- Trial name
- DIGEST (NCT01664637)
- Testing
- 10 mg TZP-102
- Where
- 35 sites in United States, Poland
- Volunteers
- 120 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis
The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis
The purpose of this study is to assess the pharmacodynamic effects (gastric emptying), safety, tolerability, and pharmacokinetics of single doses of GSK962040 in Type 1 diabetic patients with gastroparesis.
- Trial name
- NCT00861809
- Testing
- GSK962040 25 mg, GSK962040 50 mg, GSK962040 1250 mg
- Where
- 2 sites in Belgium, Sweden
- Volunteers
- 11 people
- Sponsor
- GlaxoSmithKline
Gastroparesis
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying
The purposes of this study are to determine whether an experimental drug known as tadalafil can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal, bloating, discomfort or pain in the upper…
- Trial name
- NCT00050609
- Testing
- tadalafil
- Where
- 12 sites in Canada
- Volunteers
- 2 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis
A Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) for TAK-906 in Participants With Diabetes Mellitus and Gastroparesis (DG) or With Idiopathic Gastroparesis (IG)
The purpose of this study is to evaluate the safety, PK and PD of TAK-906 in participants with Gastroparesis (GP).
- Trial name
- NCT03268941
- Testing
- TAK-906 Maleate, Metaclopramide
- Where
- 9 sites in United States
- Volunteers
- 51 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Gastroparesis
Different Doses of Naronapride vs. Placebo in Gastroparesis
This is a double-blind, randomized, multicenter, placebo-controlled, comparative phase II dose-finding trial. The trial will be conducted with four treatment groups in the form of a parallel group comparison and will serve to…
- Trial name
- MOVE-IT (NCT05621811)
- Testing
- Naronapride
- Where
- 24 sites in United States, Belgium
- Volunteers
- 328 people
- Sponsor
- Dr. Falk Pharma GmbH
Diabetic Gastroparesis
A Scintigraphy Study in Adults With Diabetic Gastroparesis
This is a randomized, double-blind, placebo-controlled scintigraphy study to investigate the effect of oral CIN-102 on gastric emptying and antral contractility in adults with diabetic gastroparesis.
- Trial name
- NCT04208698
- Testing
- CIN-102 Dose 1, CIN-102 Dose 2
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- CinDome Pharma, Inc.
Gastroparesis, Diabetes
Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis
This study will assess gastric emptying in patients with symptoms of diabetic gastroparesis treated with tegaserod over 2 weeks.
- Trial name
- NCT00390975
- Testing
- Tegaserod
- Where
- 3 sites in United States
- Volunteers
- 40 people
- Sponsor
- Novartis
Diabetes Mellitus, Diabetes Mellitus Complications
Phase 2 Study to Evaluate Safety & Efficacy of RM-131 Administered to Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the effects of RM-131 on gastric emptying, gastroparesis symptoms, and the safety and tolerability of RM-131 compared to placebo in patients with Type 1 and Type 2 diabetes mellitus and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Trial name
- NCT01571297
- Testing
- RM-131
- Where
- 30 sites in United States
- Volunteers
- 204 people
- Sponsor
- Motus Therapeutics, Inc.
Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications
Study to Assess Pharmacodynamics of RM-131 in Patients With Diabetic Gastroparesis
The purpose of this study is to evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) profile and the safety and tolerability of RM-131 in patients with diabetes mellitus and delayed gastric emptying.
- Conditions
- Diabetes Mellitus Type 1 and 2, Diabetes Mellitus Complications, Gastroparesis, Gastrointestinal Motility Disorder
- Trial name
- NCT01394055
- Testing
- RM-131
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Motus Therapeutics, Inc.
Gastroparesis
A Study of CNSA-001 in Women With Diabetic Gastroparesis
This study evaluates CNSA-001 (sepiapterin) in the treatment of women with moderate to severe diabetic gastroparesis. Participants will be randomized in a ratio of 1:1 to receive CNSA-001 20 (milligrams) mg/kilogram (kg)/day or…
- Trial name
- NCT03712124
- Testing
- CNSA-001
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- PTC Therapeutics
Gastroparesis, Diabetic Gastroparesis
Single-Patient Expanded Access Protocol for Tradipitant In A Single Patient With Gastroparesis
Primary Objective: To treat a single patient with gastroparesis who has requested expanded access with tradipitant
- Trial name
- NCT04474990
- Testing
- Tradipitant
- Where
- 15 sites in United States
- Sponsor
- Vanda Pharmaceuticals
Diabetic Gastroparesis
Trial of IW-9179 in Patients With Diabetic Gastroparesis (DGP)
The objectives of this study are to evaluate the safety of IW-9179 in patients with diabetic gastroparesis (DGP) and the effect of treatment on the cardinal symptoms of DGP.
- Trial name
- NCT02289846
- Testing
- IW-9179
- Where
- 22 sites in United States
- Volunteers
- 90 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Gastroparesis, Gastroparesis Nondiabetic
Study of Enhanced Programming Stimulation with the Enterra® Therapy System
The purpose of this research study is to evaluate if an enhanced Enterra device programming strategy will improve symptoms associated with gastroparesis, improve symptoms in a faster amount of time, and improve quality of life…
- Conditions
- Gastroparesis, Gastroparesis Nondiabetic, Gastroparesis Due to Diabetes Mellitus
- Trial name
- EXPEDITE (NCT06560307)
- Testing
- Enterra Therapy System
- Where
- 6 sites in United States
- Volunteers
- 50 people
- Sponsor
- Enterra Medical, Inc.
Gastroparesis, Diabetes Mellitus
Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus
The purpose of this study is to evaluate the effect of TZP-102 on gastric emptying rate, gastroparesis symptoms and health-related quality of life in diabetic patients with gastroparesis.
- Trial name
- NCT00889486
- Testing
- TZP-102
- Where
- 23 sites in United States, Denmark and 4 more
- Volunteers
- 92 people
- Sponsor
- Tranzyme, Inc.
Diabetic Gastroparesis
A Randomized, Open-label, Two-way Crossover Trial to Determine the Pharmacokinetics of Metoclopramide When Administered as the Orally Disintegrating Tablet Compared to Reglan® Tablets in Subjects With Diabetic Gastroparesis
To determine whether a new Orally Disintegrating Tablet of Reglan (metoclopramide) is metabolized faster than the conventional Reglan tablet in patients with diabetic gastroparesis, pharmacokinetics following a single 10 mg dose…
- Trial name
- NCT00139893
- Testing
- Reglan ODT
- Where
- United States
- Sponsor
- UCB Pharma
Gastroparesis, Diabetes Mellitus, Type 1
Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis
The purpose of this study is to test the safety and effectiveness of two dosage levels (10mg and 20mg) of TZP-102 compared to placebo (capsule that looks like the study drug but contains no active drug), administered once-daily…
- Conditions
- Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT01452815
- Testing
- 10mg TZP-102, 20mg TZP-102
- Where
- 52 sites in United States, Belgium and 6 more
- Volunteers
- 201 people
- Sponsor
- Tranzyme, Inc.
Gastroparesis, Diabetes Mellitus
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02
This study will evaluate the safety and efficacy of relamorelin compared to placebo in participants with diabetic gastroparesis. Participants will report daily severity scores of their diabetic gastroparesis symptoms.
- Trial name
- NCT03426345
- Testing
- Relamorelin
- Where
- 240 sites in United States, Argentina and 13 more
- Volunteers
- 311 people
- Sponsor
- Allergan
Diabetes Mellitus, Diabetes Mellitus Complications
Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis
The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1 and Type 2 diabetes mellitus and…
- Conditions
- Diabetes Mellitus, Diabetes Mellitus Complications, Gastroparesis
- Trial name
- NCT02357420
- Testing
- Relamorelin
- Where
- 98 sites in United States, Belgium and 5 more
- Volunteers
- 393 people
- Sponsor
- Allergan